Refine by
Hip Arthroplasty Articles & Analysis: Older
9 news found
On-site booth will host interactive experiences including product trials, hands-on demonstrations, and education Today, Johnson & Johnson MedTech* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, has acquired CUPTIMIZE™ Hip-Spine Analysis, giving surgeons an easy-to-use tool to better understand and address the impact of abnormal ...
Significant findings of Evoke ECAP-controlled closed-loop in the EVOKE Study at 24 months include: Superiority in treatment of overall back and leg pain and long-term pain reduction Highest long-term responder (≥50% relief) and high responder (≥80% relief) rates, 84% and 50%, respectively Highest reported improvements in overall quality of life, pain relief, ability to perform daily ...
Philippe Van Overschelde, a leading hip and knee arthroplasty surgeon. ‘I started testing the soft implant on patients with advanced OA who would not typically report any improvement in their symptoms, even after multiple injections of hyaluronic acid. ...
Ortho Development Corporation (ODEV) hosted the bi-annual Utah Hip and Knee Arthroplasty Symposium (UHKAS) in Park City, Utah on April 14-17, 2021. ...
The new OrthoGrid Hip is the latest version of OrthoGrid System’s patented, distortion-correcting, implant-agnostic, intraoperative-alignment technology for direct anterior hip total hip arthroplasty (DAA THA) offered on the company’s AI-enabled digital platform. ...
OrthoGrid® Systems, Inc., a global medtech leader on a mission to digitally transform intraoperative musculoskeletal surgery, announces the publication of new clinical data supporting the use of its analog and digital technology in the Journal of Arthroplasty (JOA). The article, entitled “Comparison of Component Placement Accuracy Using Two Intraoperative Fluoroscopic ...
The Libertas TR rounds out their comprehensive array of options for primary total hip arthroplasty. The reduced distal taper minimizes fracture risk and allows optimal proximal fixation, without ever getting caught up distally. ...
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in AKST6021-211, a phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, administered before and after primary hip or knee arthroplasty, to provide key insights ...
Withdrawn Rationale: This practice covers a method for the fatigue testing of metallic stemmed femoral components used in hip arthroplasty. The described method is intended to be used for evaluation in comparisons of various designs and materials used for stemmed femoral components ...